CD163 and neoplasm: It is reported ovarian cancer cells polarize macrophages toward an M2 phenotype in vivo which gradually gain expression of M2-like marker genes, such as CD206, Arg1, and CD163, at 4–8 weeks after tumor injection (Yin et al., 2016).